Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
By F. Loupakis, C. Cremolini, G. Masi, S. Lonardi, V. Zagonel, L. Salvatore, E. Cortesi, G. Tomasello, M. Ronzoni, R. Spadi and 10 more. New England Journal of Medicine, 2014
959 citations recorded by the source corpus.
Subfields: Biotechnology, Oncology
View Paper: https://www.semanticscholar.org/paper/76474f820f774cb4fa2eb664801e0ee51333b2e0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient ”
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “90) NS 2 [109]”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “Also, consideration of the other available data from these studies [176, 177, 180] clearly shows both FOLFOX and FOLFIRI to be active in combination with EGFR inhibitors in patients with RAS wild-type disease in this treatment setting, while FOLFOXIRI plus (or minus) bevacizumab has been shown to be”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, neutral): “The TRI‑ COLORE trial, a phase III trial conducted in Japan, compared the efficacy and safety of S‑1 + IRI + BEV with FOLFOX + BEV or CAPOX + BEV as first‑line therapy for PS 0–1 patients with unresectable colorectal cancer.”